Etomay, Rosenda G.
HRN: 16-24-09 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/30/2023
AMPICILLIN 1GM + SULBACTAM 500MG (VIAL)
11/30/2023
12/07/2023
IV
1.5
Q6
DM Foot
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes